Barclays’s Viking Therapeutics VKTX Stock Holding History

Barclays’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.56M	Buy	+140,000	New	+$4.5M	﹤0.01%	1877
2024 Q3	–	Sell	-80,000	Closed	-$4.24M	–	5492
2024 Q2	$4.24M	Buy	80,000 +32,300	+68%	+$2.12M	﹤0.01%	1640
2024 Q1	$3.91M	Buy	+47,700	New	+$2.12M	﹤0.01%	2027
2018 Q4	–	Sell	-25,000	Closed	-$436K	–	7363
2018 Q3	$436K	Buy	+25,000	New	+$298K	﹤0.01%	4389

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Barclays's VKTX Position: Q1 2026 in Review

Barclays reduced its Viking Therapeutics (VKTX) stake by 86% in Q1 2026, selling an estimated $14.3M and leaving 70,279 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Barclays first reported a position in VKTX in Q4 2017 and has held it in 34 quarters since. The position peaked at $18.2M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Barclays held 70,279 shares of Viking Therapeutics worth $2.29M as of Q1 2026.
Barclays sold 446,377 Viking Therapeutics shares in Q1 2026, an estimated $14.3M.
Viking Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2269 holding.
Barclays first reported a position in Viking Therapeutics in Q4 2017 and has held it in 34 quarters since.
Barclays's Viking Therapeutics position peaked at $18.2M in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.